Key result
In rats with angiotensin II-induced hypertension, continuous infusion of a thromboxane synthesis inhibitor resulted in lower mean arterial pressure (120 vs 143 mm Hg) compared to vehicle.
Why the study?
Does thromboxane synthesis inhibition reduce mean arterial pressure in rats with angiotensin II-induced hypertension?
Population
27 chronically instrumented rats
Comparison
Thromboxane synthesis inhibitor U63557A i.v… vs Vehicle i.v. infusion
Design
Preclinical
Follow-up
7 days
Authors
Loading...
Thromboxane inhibition attenuates angiotensin II hypertension in rats; leaves open any human therapeutic role.
Does thromboxane synthesis inhibition reduce mean arterial pressure in rats with angiotensin II-induced hypertension?
Absolute Event Rate: 120% vs 143%
Endogenous thromboxane is an important determinant of mean arterial pressure in angiotensin II-induced hypertension, but has a diminished role when ANG II levels are normal or subnormal.
Keen et al. (1997) studied Angiotensin II-induced hypertension (n=27). Thromboxane synthesis inhibitor (TSI) U63557A vs. Vehicle was evaluated on Mean arterial pressure (MAP) after 7 days of high-dose ANG II (20 ng.kg-1.min-1). In rats with angiotensin II-induced hypertension, continuous infusion of a thromboxane synthesis inhibitor resulted in lower mean arterial pressure (120 vs 143 mm Hg) compared to vehicle.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: